Alpha Oncology Research LLC

1. E.R. Squibb & Sons, L.L.C. $293,548 11 payments
2. Eli Lilly and Company $139,338 6 payments
3. Merck Sharp & Dohme Corporation $121,653 4 payments
4. G1 Therapeutics, Inc. $115,021 70 payments
5. Mirati Therapeutics, Inc. $111,887 42 payments
6. AstraZeneca Pharmaceuticals LP $85,487 2 payments
7. AstraZeneca UK Limited $84,373 3 payments
8. Veloxis Pharmaceuticals, Inc. $71,416 3 payments
9. Secura Bio, Inc. $66,011 9 payments
10. Pfizer Inc. $63,755 9 payments

1. A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1 $109,697 41 payments
2. Ember-3: A Randomized, Open-Label, Phase 3 Study of Ly3484356 VS Investigator's Choice of Endocrine Therapy, in Patients With Estrogen Receptor Positive, Her2 Negative Locally Advanced Or Metastatic Breast Cancer Previously Treated With Endocrine Therapy $104,685 2 payments
3. PhII MORAb-202 in 2L/3L mNSCLC - A Phase II Open Label Randomized Study of MORAb-202 (farletuzumab ecteribulin, an antibody drug conjugate) in participants with metastatic non-small cell lung cancer (NSCLC) adenocarcinoma after progression on prior therap $99,276 4 payments
4. A Phase 3, Randomized, Double-Blind Study of COSELA or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE-2) $90,773 61 payments
5. Study of Durvalumab Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy $56,688 1 payment
6. Assess Safety and Tolerability of ART-123 and FOLFOX Bevacizumab in Metastatic Colorectal Cancer Patients $52,577 1 payment
7. A Two-Part Randomized, Phase 3 Study of Combinations of Cemiplimab (Anti-Pd-1 Antibody) and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer $51,462 15 payments
8. Phase IIA 1L Stage IV NSCLC - A Randomized, Double-Blind, Phase 2 Study of BMS-986315 and Nivolumab in Combination with Chemotherapy versus Nivolumab in Combination with Chemotherapy as First-line Treatment for Participants with Stage IV or Recurrent No $47,208 1 payment
9. An open-label, randomized, Phase 3 clinical trial of IO102-IO103 in combination withpembrolizumab versus pembrolizumab alone in patients with previously untreated,unresectable, or metastatic advanced melanoma $46,992 1 payment
10. Ph2 Randomized Single Dbl Blind 1L NSCLC (TIGIT + Nivo/IPI vs Nivo/Ipi) $43,788 2 payments

1. Non-patient care $92,483 39 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.